Measles in depth.

Overview

Measles is a highly contagious viral disease caused by Morbillivirus — a paramyxovirus with a single-stranded, negative-sense RNA genome. With a basic reproduction number (R0) of 12–18, measles is the most infectious human pathogen known — one infected person can spread the virus to 12–18 susceptible individuals. The virus spreads through airborne droplet nuclei so efficiently that it can infect susceptible persons who enter a room up to two hours after an infected person has left.

Before widespread vaccination, measles infected virtually every child — with an estimated 130 million cases per year globally. The introduction of the measles vaccine in 1963 and subsequent global vaccination programs dramatically reduced measles incidence and deaths. WHO estimates that between 2000 and 2022, measles vaccination prevented approximately 57.7 million deaths. Yet measles still killed approximately 136,000 people in 2022 (WHO estimate), the vast majority children under 5 in sub-Saharan Africa.

Measles has been resurging globally since the mid-2010s and accelerated further following COVID-19, which disrupted routine immunization programs worldwide. An estimated 22 million children missed their first measles dose in 2020. The DRC has faced the world's largest measles epidemic — over 300,000 cases and 6,000+ deaths in 2019 alone. Vaccine hesitancy-driven outbreaks have occurred in high-income countries including the US, UK, and across Europe. Achieving and maintaining 95%+ vaccination coverage in all communities is the only path to measles control and eventual elimination.

History & Origin

Measles is an ancient human disease — genetic analysis suggests it diverged from rinderpest (cattle disease) around 500 BCE as agricultural civilizations brought humans and cattle into close contact. The first scientific description is attributed to the Persian physician Rhazes (Abu Bakr al-Razi) in the 9th century CE, who distinguished measles from smallpox. Measles epidemics devastated indigenous populations with no prior exposure — including Hawaii (1848, killing ~30,000 in months) and the Faroe Islands (1846, studied by Peter Panum in a landmark epidemiological investigation).

John Franklin Enders and Thomas Peebles isolated measles virus in 1954, enabling vaccine development. The first licensed measles vaccine was introduced in 1963 (killed virus vaccine, quickly replaced by live attenuated version). John Enders received the Nobel Prize in 1954 for his cell culture work foundational to many virus vaccine developments. The MMR (measles-mumps-rubella) combination vaccine was licensed in 1971. Maurice Hilleman's team at Merck developed the highly effective Moraten strain used in most vaccines today.

Transmission

• Airborne: Droplet nuclei containing measles virus can remain suspended in the air for up to 2 hours in enclosed spaces. Susceptible persons entering a room after an infected person has left can still be infected.
• Respiratory droplets: Direct contact with large respiratory droplets expelled by coughing or sneezing from an infected person.
• Infectiousness period: A person with measles is infectious from approximately 4 days before the rash appears until 4 days after rash onset — during which they may feel relatively well and not know they are infectious.
• No animal reservoir: Measles has no animal reservoir — humans are the only natural host. This makes measles eradication theoretically achievable with a sufficiently effective and widely deployed vaccine (as was achieved with smallpox).
• Herd immunity threshold: Due to the very high R0 (12–18), herd immunity against measles requires at least 95% of the population to be immune. Any fall below this threshold creates pockets of susceptible individuals where outbreaks can ignite.

Symptom Timeline

The incubation period is 7–21 days (typically 10–14 days to rash onset). Measles follows a characteristic progression through three clinical phases.

Diagnosis

• Clinical diagnosis: Classic triad (fever + rash + cough/coryza/conjunctivitis) + Koplik spots in epidemiological context is sufficient for clinical diagnosis. However, laboratory confirmation is required for outbreak investigation and surveillance.
• IgM serology: Measles-specific IgM antibodies in serum or dried blood spot — appear from rash day 1–3; highly sensitive and specific. Standard confirmatory test in clinical practice.
• RT-PCR: Detection of measles virus RNA in throat swab, nasopharyngeal swab, or urine — most sensitive in the first 3 days after rash onset. Allows genotyping for outbreak investigation (determining transmission chains).
• Viral isolation: Culture of measles virus — gold standard but slow; used in reference laboratories for research and characterization.
• WHO case definition: Generalized maculopapular rash ≥3 days + fever ≥38.3°C + cough OR coryza OR conjunctivitis. Suspected cases should be tested even if vaccinated — vaccine failure (primary or secondary) is possible.

Treatment

No specific antiviral therapy is approved for measles. Management is supportive with vitamin A supplementation playing a critical role.

• Vitamin A supplementation: WHO strongly recommends vitamin A for all children with measles in resource-limited settings. Vitamin A deficiency (common in sub-Saharan Africa and South Asia) dramatically worsens measles severity and mortality. Two doses of age-appropriate vitamin A (200,000 IU for children >1 year, 100,000 IU for 6–12 months) reduce measles mortality by up to 50%.
• Fever management: Paracetamol; cool sponging. Avoid aspirin in children (Reye syndrome risk).
• Hydration and nutrition: Adequate fluid intake; nutritional support for malnourished children.
• Antibiotic therapy: For bacterial superinfections (pneumonia, otitis media) — guided by clinical assessment. NOT for measles itself (viral disease).
• Hospital admission: Required for complications: pneumonia (oxygen therapy, antibiotics), dehydration, encephalitis (supportive neurological care), severe malnutrition.
• Ribavirin: Used in some severe immunocompromised cases — not standard of care.

Prevention & Vaccines

• MMR vaccine: Live attenuated combined measles-mumps-rubella vaccine. One dose provides ~93% protection; two doses ~97% protection. WHO recommends two doses: first at 9–12 months (9 months in high-transmission settings), second at 15–18 months or school entry.
• MMRV: Combined measles-mumps-rubella-varicella vaccine — reduces the number of injections needed.
• Herd immunity threshold: 95% vaccination coverage required to interrupt measles transmission. Any community below this threshold is at risk of outbreaks when the virus is introduced.
• Post-exposure prophylaxis: MMR vaccine given within 72 hours of exposure can prevent or attenuate measles. Measles immunoglobulin (MIG) given within 6 days can prevent measles in high-risk contacts (infants, immunocompromised).
• Supplementary Immunization Activities (SIAs): Mass vaccination campaigns targeting children who may have missed routine doses — critical tool for rapidly boosting population immunity and controlling outbreaks.

Global Impact

Measles caused approximately 136,000 deaths in 2022 (WHO estimate) — a dramatic reversal from the record low of ~73,000 deaths in 2020. Global measles cases increased sharply in 2022 and 2023 as COVID-19 disrupted immunization programs and accumulated immunity gaps materialized into outbreaks. WHO and UNICEF estimated that 40 million children missed measles vaccinations in 2020 alone.

The DRC continues to bear the world's largest measles burden — with over 100,000 cases and thousands of deaths annually, the DRC measles epidemic dwarfs other outbreaks. In 2019, DRC reported over 300,000 cases — more than the entire rest of the world combined. Measles outbreaks in conflict zones (Somalia, Yemen, Syria, South Sudan) are particularly deadly due to malnutrition, poor healthcare access, and inability to reach children for vaccination in active conflict areas.

In high-income countries, measles was eliminated (interruption of endemic transmission) but continues to cause outbreaks imported from endemic regions into unvaccinated communities. The US declared measles eliminated in 2000, but has experienced multiple outbreaks driven by vaccine-hesitant communities — including a 2019 outbreak of 1,282 cases (the largest in 27 years). European countries including France, Italy, Romania, and Ukraine have all experienced large measles outbreaks in recent years.

Country-Specific Information

DRC: The world's largest measles outbreak is in the DRC, which reports over 100,000 cases annually. The 2019–2020 outbreak killed over 6,700 people — more than the concurrent Ebola outbreak in the same country. Conflict, displacement, low vaccination coverage, and a young unvaccinated population drive the epidemic. DRC is a major focus of WHO/UNICEF SIA campaigns.

Somalia: Somalia has extremely low measles vaccination coverage (<40% in some regions), contributing to recurrent outbreaks in a population with significant accumulated immunity gaps. Humanitarian crises, malnutrition, and conflict zone access restrictions complicate outbreak response.

Ethiopia: Ethiopia reports recurrent measles outbreaks particularly in pastoralist communities in remote regions with poor vaccination access. The country has implemented mobile vaccination teams to reach nomadic communities.

Nigeria: Nigeria has the highest measles burden in West Africa. Outbreaks occur regularly in northern states with lower vaccination coverage. Nigeria is a priority country for WHO/GAVI measles vaccination support.

Frequently Asked Questions

Sources & Citations

Related Diseases